Literature DB >> 28654784

Generation and characterization of a human oral squamous carcinoma cell line SCC-9 with CRISPR/Cas9-mediated deletion of the p75 neurotrophin receptor.

Ping Huang1, Dongdong Tong2, Jing Sun3, Qing Li2, Fenghe Zhang4.   

Abstract

OBJECTIVE: To investigate the importance of the p75 neurotrophin receptor (p75NTR) in human tongue squamous carcinoma cells, we exploited the CRISPR/Cas9 technology to establish a p75NTR-knockout SCC-9 cell line and to explore the effect on biological functions.
MATERIALS AND METHODS: The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease (Cas9) system was used to generate genomic deletion mutants of p75NTR in the tongue squamous carcinoma cell lines SCC-9. Single-guide RNA (sgRNA) sequences were designed to target the p75NTR genomic sequence and were cloned into plasmid pGK1.1. The linearized vector was electroporated into SCC-9 cells and p75NTR deletion was confirmed using Cruiser™ enzyme digestion and PCR amplification. SCC-9 clones with successful deletion of p75NTR were identified and verified by sequencing and selected for functional testing in cell proliferation, invasion, migration, and colony-forming assays.
RESULTS: Compared with control cells, p75NTR-knockout SCC-9 cells showed significantly diminished abilities to proliferate, invade, migrate, and form colonies, indicating a reduction in pro-tumorigenic behavior.
CONCLUSION: These data demonstrate, first, that the CRISPR/Cas9 system is a simplified method for generating p75NTR knockouts with relatively high efficiency, and second, that deletion of p75NTR suppresses several tumor-promoting properties of SCC-9 cells, suggesting that p75NTR is a potential target for the development of novel therapies for tongue cancer.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CRISPR/Cas9; Cruiser(TM); Enzyme; Knockout; Oral squamous carcinoma; Therapy; p75(NTR)

Mesh:

Substances:

Year:  2017        PMID: 28654784     DOI: 10.1016/j.archoralbio.2017.06.004

Source DB:  PubMed          Journal:  Arch Oral Biol        ISSN: 0003-9969            Impact factor:   2.633


  5 in total

Review 1.  Genome Editing: A New Horizon for Oral and Craniofacial Research.

Authors:  N Yu; J Yang; Y Mishina; W V Giannobile
Journal:  J Dent Res       Date:  2018-10-24       Impact factor: 6.116

2.  [Development of precancerous lesions of oral mucous membrane diseases and oral cancer animal models].

Authors:  Jun-Xin Cheng; He-Tian Bai; Zhi-Nan Chang; Jing Li; Qian-Ming Chen
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-04-01

Review 3.  CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity.

Authors:  Tao Xu; Li Li; Yu-Chen Liu; Wei Cao; Jia-Si Chen; Shuang Hu; Ying Liu; Liang-Yun Li; Hong Zhou; Xiao-Ming Meng; Cheng Huang; Lei Zhang; Jun Li; Huan Zhou
Journal:  Int J Biol Sci       Date:  2020-06-01       Impact factor: 6.580

4.  CRISPR/Cas9-Mediated OC-2 Editing Inhibits the Tumor Growth and Angiogenesis of Ovarian Cancer.

Authors:  Tongyi Lu; Ligang Zhang; Wenhui Zhu; Yinmei Zhang; Simin Zhang; Binhua Wu; Ning Deng
Journal:  Front Oncol       Date:  2020-09-02       Impact factor: 6.244

5.  Prolactin (PRL), placenta growth factor (PIGF) and nerve growth factor receptor (NGFR) as biomarkers for early diagnosis and prognosis in patients with esophageal squamous cell carcinoma (ESCC).

Authors:  Xiaohong Ai; Xiaoxi Zhu; Jianhong Zuo
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.